Is NKTX or STTK more profitable?

Nkarta's return on equity of -39.64% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Shattuck Labs N/A -43.57% -40.90%

Does the media favor NKTX or STTK?

In the previous week, Shattuck Labs had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Shattuck Labs and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Shattuck Labs' score of 1.03 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Shattuck Labs 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TECX or NKTX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A Nkarta N/A N/A -$104.08M -$1.57 N/A

Is TECX or NKTX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Nkarta N/A -39.64% -30.45%

Does the media favor TECX or NKTX?

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Nkarta. MarketBeat recorded 6 mentions for Tectonic Therapeutic and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Tectonic Therapeutic's score of 1.01 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, BBOT or NKTX?

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A Nkarta N/A N/A -$104.08M -$1.57 N/A

Is BBOT or NKTX more profitable?

Nkarta's return on equity of -39.64% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BridgeBio Oncology Therapeutics N/A -46.90% -42.17% Nkarta N/A -39.64% -30.45%

Which has better earnings and valuation, NKTX or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A

Is NKTX or MNPR more profitable?

Monopar Therapeutics' return on equity of -13.08% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Monopar Therapeutics N/A -13.08% -12.79%

Does the media favor NKTX or MNPR?

In the previous week, Monopar Therapeutics had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Monopar Therapeutics' score of 0.73 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Monopar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALLO or NKTX more profitable?

Nkarta's return on equity of -39.64% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Nkarta N/A -39.64% -30.45%

Does the media prefer ALLO or NKTX?

In the previous week, Allogene Therapeutics had 11 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Allogene Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Allogene Therapeutics' score of 0.85 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Nkarta (NKTX) Competitors

$2.71 -0.05 (-1.81%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$2.68 -0.04 (-1.29%)

As of 07:53 AM Eastern

Compare

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

Should you buy Nkarta stock or one of its competitors? Nkarta's main competitors and comparable companies include Shattuck Labs (STTK), Tectonic Therapeutic (TECX), BridgeBio Oncology Therapeutics (BBOT), Monopar Therapeutics (MNPR), and Allogene Therapeutics (ALLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nkarta compare to Shattuck Labs?

Nkarta (NASDAQ:NKTX) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Nkarta's return on equity of -39.64% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Shattuck Labs	N/A	-43.57%	-40.90%

Shattuck Labs has higher revenue and earnings than Nkarta. Shattuck Labs is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Shattuck Labs	$1M	703.52	-$48.81M	-$0.51	N/A

Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Shattuck Labs had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Shattuck Labs and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Shattuck Labs' score of 1.03 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Shattuck Labs	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nkarta presently has a consensus target price of $11.20, suggesting a potential upside of 313.28%. Shattuck Labs has a consensus target price of $12.78, suggesting a potential upside of 82.28%. Given Nkarta's higher possible upside, equities research analysts plainly believe Nkarta is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Shattuck Labs beats Nkarta on 8 of the 15 factors compared between the two stocks.

How does Nkarta compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Tectonic Therapeutic presently has a consensus target price of $77.80, indicating a potential upside of 159.85%. Nkarta has a consensus target price of $11.20, indicating a potential upside of 313.28%. Given Nkarta's higher probable upside, analysts clearly believe Nkarta is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Nkarta. MarketBeat recorded 6 mentions for Tectonic Therapeutic and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Tectonic Therapeutic's score of 1.01 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Tectonic Therapeutic's return on equity of -35.26% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Nkarta	N/A	-39.64%	-30.45%

Summary

Tectonic Therapeutic and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

How does Nkarta compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.40, suggesting a potential upside of 177.27%. Nkarta has a consensus price target of $11.20, suggesting a potential upside of 313.28%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nkarta's return on equity of -39.64% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Nkarta	N/A	-39.64%	-30.45%

BridgeBio Oncology Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

In the previous week, Nkarta had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for BridgeBio Oncology Therapeutics. Nkarta's average media sentiment score of 1.78 beat BridgeBio Oncology Therapeutics' score of 0.93 indicating that Nkarta is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Positive
Nkarta	Very Positive

Summary

Nkarta beats BridgeBio Oncology Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Nkarta compare to Monopar Therapeutics?

Nkarta (NASDAQ:NKTX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics' return on equity of -13.08% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Nkarta presently has a consensus target price of $11.20, indicating a potential upside of 313.28%. Monopar Therapeutics has a consensus target price of $118.67, indicating a potential upside of 6.02%. Given Nkarta's higher possible upside, equities analysts clearly believe Nkarta is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

In the previous week, Monopar Therapeutics had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Monopar Therapeutics' score of 0.73 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Monopar Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Summary

Monopar Therapeutics beats Nkarta on 7 of the 13 factors compared between the two stocks.

How does Nkarta compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Allogene Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

In the previous week, Allogene Therapeutics had 11 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Allogene Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Allogene Therapeutics' score of 0.85 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nkarta has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,549.00	-$190.89M	-$0.67	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Allogene Therapeutics currently has a consensus target price of $8.30, suggesting a potential upside of 315.00%. Nkarta has a consensus target price of $11.20, suggesting a potential upside of 313.28%. Given Allogene Therapeutics' higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Nkarta's return on equity of -39.64% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Nkarta	N/A	-39.64%	-30.45%

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Allogene Therapeutics and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$197.68M	$3.94B	$7.20B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	10.96%
P/E Ratio	-1.73	11.63	272.60	25.50
Price / Sales	N/A	1,350.81	626.13	97.73
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.62	16.74	11.03	6.34
Net Income	-$104.08M	-$22.72M	$3.47B	$349.45M
7 Day Performance	N/A	1.01%	0.12%	-0.67%
1 Month Performance	29.67%	13.06%	8.14%	4.48%
1 Year Performance	27.83%	54.92%	24.11%	14.94%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	3.3482 of 5 stars	$2.71 -1.8%	$11.20 +313.3%	+27.8%	$197.68M	N/A	N/A	140	Positive News
STTK Shattuck Labs	3.6688 of 5 stars	$7.90 +4.9%	$12.78 +61.7%	+614.7%	$755.73M	$1M	N/A	100	Positive News High Trading Volume
TECX Tectonic Therapeutic	2.7055 of 5 stars	$36.47 -3.1%	$77.80 +113.3%	+17.2%	$735.64M	N/A	N/A	120	News Coverage Positive News
BBOT BridgeBio Oncology Therapeutics	2.481 of 5 stars	$9.14 +0.7%	$24.40 +167.0%	N/A	$727.98M	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.1251 of 5 stars	$111.36 +3.4%	$118.67 +6.6%	+227.8%	$723.03M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

How does Nkarta compare to Shattuck Labs?

Summary

How does Nkarta compare to Tectonic Therapeutic?

Summary

How does Nkarta compare to BridgeBio Oncology Therapeutics?

Summary

How does Nkarta compare to Monopar Therapeutics?

Summary

How does Nkarta compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

How does Nkarta compare to Shattuck Labs?

Is NKTX or STTK more profitable?

Which has preferable earnings and valuation, NKTX or STTK?

Which has more volatility & risk, NKTX or STTK?

Does the media favor NKTX or STTK?

Do institutionals and insiders hold more shares of NKTX or STTK?

Do analysts rate NKTX or STTK?

Summary

How does Nkarta compare to Tectonic Therapeutic?

Do analysts prefer TECX or NKTX?

Which has preferable earnings & valuation, TECX or NKTX?

Does the media favor TECX or NKTX?

Do insiders and institutionals believe in TECX or NKTX?

Which has more volatility and risk, TECX or NKTX?

Is TECX or NKTX more profitable?

Summary

How does Nkarta compare to BridgeBio Oncology Therapeutics?

Do analysts recommend BBOT or NKTX?

Do insiders & institutionals hold more shares of BBOT or NKTX?

Is BBOT or NKTX more profitable?

Which has more risk and volatility, BBOT or NKTX?

Which has preferable earnings and valuation, BBOT or NKTX?

Does the media prefer BBOT or NKTX?

Summary

How does Nkarta compare to Monopar Therapeutics?

Do institutionals and insiders believe in NKTX or MNPR?

Is NKTX or MNPR more profitable?

Do analysts rate NKTX or MNPR?

Which has better earnings and valuation, NKTX or MNPR?

Does the media favor NKTX or MNPR?

Which has more volatility & risk, NKTX or MNPR?

Summary

How does Nkarta compare to Allogene Therapeutics?

Which has more risk & volatility, ALLO or NKTX?

Does the media prefer ALLO or NKTX?

Which has better earnings & valuation, ALLO or NKTX?

Do analysts rate ALLO or NKTX?

Is ALLO or NKTX more profitable?

Do institutionals and insiders hold more shares of ALLO or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools